Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Life Technologies; Qiagen; Leica Biosystems; Becton Dickinson; PerkinElmer; MOgene, Intuitive Genomics

NEW YORK (GenomeWeb News) – Life Technologies this week said that it will provide a complete workflow to researchers aiming to identify 20,000 human remains found in mass graves in Libya. Life Tech will provide a variety of forensic DNA technologies and samples will be processed by its Dubai-based distributor Integrated Gulf Biosystems. The project is being funded in part by a $2.5 million grant from Spanish oil firm Repsol.

Investment bank RW Baird raised its stock price target on Qiagen to $26 from $20 after the firm posted fourth-quarter revenues above estimates and provided 2013 guidance above Wall Street's expectations.

Leica Biosystems announced this week that it has opened an R&D facility in the Boston area of Massachusetts, which will focus on development of companion diagnostics.

The board of directors of Becton Dickinson this week declared a quarterly dividend of $.495 per common share. The dividend is payable on March 29 to holders of record on March 8.

PerkinElmer's board of directors has declared a quarterly dividend of $.07 per share. The dividend is payable on May 10 to shareholders of record as of the close of business on April 19.

MOgene announced a partnership with Intuitive Genomics this week to further expand its bioinformatics capabilities. The St. Louis-based genomics services provider didn't disclose any details of the expansion.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.